{"url": "https://www.reuters.com/article/us-fda-approval-novartis/fda-expands-use-of-novartis-ms-drug-to-pediatric-patients-idUSKBN1IC2L7", "text": "FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo\n\n(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "images": ["https://static.reuters.com/resources_v2/react/fast-track/pre-roll-admantx-ed60b222/3aae9fd5da3557fba61d6444cb943643.png", "https://s4.reutersmedia.net/resources/r/?m=02&d=20180511&t=2&i=1261066053&w=1200&r=LYNXMPEE4A1PW", "https://s4.reutersmedia.net/resources/r/?m=02&d=20180511&t=2&i=1261066053&r=LYNXMPEE4A1PW&w=20"], "top_img": "https://s4.reutersmedia.net/resources/r/?m=02&d=20180511&t=2&i=1261066053&w=1200&r=LYNXMPEE4A1PW", "keywords": [], "authors": ["Reuters Editorial", "Min Read"], "canonical_link": "https://www.reuters.com/article/us-fda-approval-novartis-idUSKBN1IC2L7", "title": "FDA expands use of Novartis MS drug to pediatric patients", "meta_data": {"robots": "index, follow", "viewport": "width=device-width, initial-scale=1, user-scalable=yes", "DCSext.ContentChannel": "healthNews", "DCSext.ChannelList": "medical-research;companies-phar;everythingNews;healthNews", "description": "The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG's relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.", "Author": "Reuters Editorial", "keywords": "US,FDA,APPROVAL,NOVARTIS,Switzerland,Company News,Health / Medicine,Content produced in Bangalore,Pharmaceuticals (TRBC),Multiple Sclerosis,Europe,Pharmaceuticals and Medical Research (TRBC),Medical Regulatory Issues", "news_keywords": "US;FDA;APPROVAL;NOVARTIS;Switzerland;Company News;Health / Medicine;Content produced in Bangalore;Pharmaceuticals (TRBC);Multiple Sclerosis;Europe;Pharmaceuticals and Medical Research (TRBC);Medical Regulatory Issues", "REVISION_DATE": "Fri May 11 21:03:54 UTC 2018", "analyticsAttributes.articleDate": "2018-05-11T21:03:54+0000", "analyticsAttributes.author": "Reuters Editorial", "analyticsAttributes.canonicalUrl": "https://www.reuters.com/article/us-fda-approval-novartis-idUSKBN1IC2L7", "analyticsAttributes.contentTitle": "FDA expands use of Novartis MS drug to pediatric patients", "analyticsAttributes.edition": "U.S.", "analyticsAttributes.keywords": "US,FDA,APPROVAL,NOVARTIS,Switzerland,Company News,Health / Medicine,Content produced in Bangalore,Pharmaceuticals (TRBC),Multiple Sclerosis,Europe,Pharmaceuticals and Medical Research (TRBC),Medical Regulatory Issues", "analyticsAttributes.keywordSlug": "US-FDA-APPROVAL-NOVARTIS", "analyticsAttributes.inlineType": "false", "analyticsAttributes.title": "FDA expands use of Novartis MS drug to pediatric patients", "sailthru.author": "Reuters Editorial", "sailthru.date": "2018-05-11T21:03:54+0000", "sailthru.title": "FDA expands use of Novartis MS drug to pediatric patients", "og": {"locale": "en_US", "site_name": "U.S.", "title": "FDA expands use of Novartis MS drug to pediatric patients", "url": "https://www.reuters.com/article/us-fda-approval-novartis-idUSKBN1IC2L7", "type": "article", "description": "The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novart...", "image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20180511&t=2&i=1261066053&w=1200&r=LYNXMPEE4A1PW", "article": {"published_time": "2018-05-11T21:03:54+0000", "modified_time": "2018-05-11T21:03:54+0000", "section": "Homepage", "author": "Reuters Editorial", "tag": "US,FDA,APPROVAL,NOVARTIS,Switzerland,Company News,Health / Medicine,Content produced in Bangalore,Pharmaceuticals (TRBC),Multiple Sclerosis,Europe,Pharmaceuticals and Medical Research (TRBC),Medical Regulatory Issues"}}, "article": {"publisher": "https://www.facebook.com/Reuters"}, "twitter": {"site": "@Reuters", "creator": "@Reuters", "card": "summary_large_image", "title": "FDA expands use of Novartis MS drug to pediatric patients", "description": "The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG's relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.", "image": {"identifier": "https://s4.reutersmedia.net/resources/r/?m=02&d=20180511&t=2&i=1261066053&w=1200&r=LYNXMPEE4A1PW", "src": "https://s4.reutersmedia.net/resources/r/?m=02&d=20180511&t=2&i=1261066053&w=1200&r=LYNXMPEE4A1PW"}}, "DCSext.DartZone": "us.reuters/tentpoles/AdvancingForward/article", "analyticsAttributes.channel": "News", "analyticsAttributes.contentType": "Article", "analyticsAttributes.contentChannel": "Homepage - Homepage", "analyticsAttributes.topicChannel": "Homepage", "analyticsAttributes.topicSubChannel": "Homepage", "msapplication-TileColor": "#ff8000", "msapplication-TileImage": "https://s2.reutersmedia.net/resources_v2/images/mstile-144x144.png", "msapplication-square70x70logo": "https://s1.reutersmedia.net/resources_v2/images/mstile-70x70.png", "msapplication-square150x150logo": "https://s1.reutersmedia.net/resources_v2/images/mstile-150x150.png", "msapplication-wide310x150logo": "https://s1.reutersmedia.net/resources_v2/images/mstile-310x150.png", "msapplication-square310x310logo": "https://s1.reutersmedia.net/resources_v2/images/mstile-310x310.png", "msapplication-config": "none", "theme-color": "#ffffff"}, "movies": [], "publish_date": 1526072634.0, "source": "https://www.reuters.com", "summary": ""}